COVID-19 vaccination in Thailand

Last updated
COVID-19 vaccination in Thailand
Date28 February 2021 (2021-02-28) – present (10 months, 2 weeks and 1 day)
Location Thailand
Cause COVID-19 pandemic in Thailand
Participants102,527,174 total doses
(24 Dec 2021) [1]
Website ddc.moph.go.th/vaccine-covid19/
dashboard-vaccine.moph.go.th

Total number of people who have received vaccinations in Thailand as of 8 Nov 2021 [1]
* Percentage of population with right to medical treatment [2]

Contents

  Unvaccinated population: ~23.003 million people (34.24%)
  Population who have received only one dose of a two-dose vaccine: 9,745,446 (14.51%)
  Population who are fully vaccinated: 31,857,851 (47.42%)
  Population who received first booster dose: 2,572,899 (3.83%)
  Population who received second booster dose: 2,809 (0.00%)

Vaccines delivered per pharmaceutical company as of 8 Nov [1]

   Oxford–AstraZeneca: ~36.606 million doses (43.78%)
   CoronaVac: ~25.508 million doses (30.50%)
   Sinopharm BIBP: ~13.231 million doses (15.82%)
   Pfizer–BioNTech: ~8.199 million doses (9.8%)
   Moderna: ~0.07 million doses (0.01%)
   Janssen: ~0.007 million doses (0.01%)

COVID-19 vaccination in Thailand is an ongoing mass immunization in response to the ongoing pandemic in the country.

Background

In November 2020, the authorities ordered 26 million doses of vaccine from AstraZeneca, which reported 70% overall efficacy. [3] It requires 2 doses of vaccine per person, so the quantity ordered would only cover 13 million people. [4] Prayut cabinet later approved budget for ordering 35 million additional doses in January 2021. [5] Siam Bioscience, a company owned by King Vajiralongkorn, will received technological transfer for co-investment. [6] The authorities also imported 2 million doses of vaccine from Sinovac, a Chinese company which Thai conglomerate Charoen Pokphand invested in, [7] during February to April 2021. [8]

Likewise, the Thai government also stepped up its attempt to produce its homegrown vaccines amidst criticism, [9] with "ChulaCov19" and set to begin trials in May 2021. [10] Phase I testing of the NDV-HXP-S vaccine began at Mahidol University in March 2021. [11] [12]

In July 2021, the National Vaccine Institute apologized for slow vaccine deployment. [13] Meanwhile, the government's prior commitment to secure 61 million doses of AstraZeneca vaccine became doubted after a leaked document showed that the company would deliver no more than 60 percent of the number planned per month. [14] A virology advisor also endorsed an untested plan to mix AstraZeneca and Sinovac vaccines. [15] There was already a report of death from the practice, but health professionals said they have to rule out other causes first. [16]

Vaccines used

National Vaccines

Free Vaccines which are provided under the policies of the Ministry of Public Health.

Vaccine nameDoses ordered

(excluding donation)

Doses arrived

(including donation)

Approval (EUA)First ArrivalDeploymentRef
Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca 61 million25.5 millionGreen check.svg 20 January 2021Green check.svg 24 February 2021Green check.svg 28 February 2021 [17] [18] [19] [20]
Flag of the People's Republic of China.svg CoronaVac 31.1 million26.52 millionGreen check.svg 22 January 2021Green check.svg 24 February 2021Green check.svg 28 February 2021 [18] [19] [20]
Flag of the United States.svg Flag of Belgium (civil).svg Janssen 5 millionunknownGreen check.svg 25 March 2021Green check.svg Late JuneGreen check.svg 26 July 2021 [21] [22] [23] [24] [20]
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech 30 million3.5 millionGreen check.svg 24 June 2021Green check.svg 30 July 2021Green check.svg 5 Aug 2021 [25] [26] [27] [18] [28] [29]

Optional Vaccines

Vaccines that are not in the policies of the Ministry of Public Health. Orders are made through government organizations but the cost of vaccination will not be supported by the government. However, people who get vaccinated by these vaccines are still counted in the national vaccination programme.

Vaccine nameDistributorDoses planned
or ordered
Doses arrivedApproval (EUA)First ArrivalDeploymentRef
Flag of the United States.svg Moderna Government Pharmaceutical Organization 5 million0.5602 millionGreen check.svg 13 May 2021Green check.svg 1 Nov 2021Green check.svg 5 Nov 2021 [21] [30] [31] [32]
Chulabhorn Royal Academy 8 millionDark Red x.svg Not yetGreen check.svg 13 May 2021Dark Red x.svg Not yetDark Red x.svg Not yet [33]
Flag of the People's Republic of China.svg Sinopharm BIBP (BBIBP-CorV) Chulabhorn Royal Academy 15 million15 millionGreen check.svg 28 May 2021Green check.svg 20 June 2021Green check.svg 25 June 2021 [21] [34] [35] [18] [36] [37]

Vaccines pending approval

Vaccination Procedures

Vaccination procedures used in Thailand. [38]

First DoseSecond DoseThird DoseFourth DoseDose Interval
Flag of the People's Republic of China.svg CoronaVac
or
Flag of the People's Republic of China.svg Sinopharm BIBP
Flag of the People's Republic of China.svg CoronaVac
or
Flag of the People's Republic of China.svg Sinopharm BIBP
Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca
or
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca
or
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
2–4 weeks [39] (2nd)
4 weeks (3rd)
3 month (4th)
Flag of the People's Republic of China.svg CoronaVac
or
Flag of the People's Republic of China.svg Sinopharm BIBP
Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca
or
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca
or
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
3–4 weeks (2nd)
3 month (3rd and 4th)
Flag of the People's Republic of China.svg CoronaVac
or
Flag of the People's Republic of China.svg Sinopharm BIBP
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
3–4 weeks (2nd)
6 month (3rd)
3 month (4th)
Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
10–16 weeks (2nd)
3 month (3rd and 4th)
Flag of the United Kingdom.svg Flag of Sweden.svg Oxford–AstraZeneca Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
4–12 weeks (2nd)
6 month (3rd)
3 month (4th)
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
Flag of the United States.svg Flag of Germany.svg Pfizer–BioNTech
or
Flag of the United States.svg Moderna
4–12 weeks (2nd)
6 month (3rd)
3 month (4th)

Notes

Vaccines in trial stage

VaccineType (technology)Progress
Flag of Thailand.svg Flag of the United States.svg NDV-HXP-S (HXP-GPOVac)
Mahidol University, University of Texas at Austin,
Newcastle disease virus (NDV) viral vector
(expressing the spike protein of SARS-CoV-2,
with or without the adjuvant CpG 1018) or Inactivated
Phase I–II (460) [42]
Randomized, placebo-controlled, observer-blind.
Mar 2021 May 2022; Thailand [43]
Flag of Thailand.svg ChulaCov19
Chulalongkorn University
RNA Phase I–II (96) [44]
Dose-finding Study.
Jan–Mar 2021, Thailand
Flag of Thailand.svg Baiya SARS-CoV-2 Vax 1 [45]
Baiya Phytopharm Co Ltd.
Plant-based Subunit (RBD-Fc + adjuvant)Phase I (96) [46]
Randomized, open-label, dose-finding.
Sep–Dec 2021, Thailand
Flag of Australia (converted).svg Flag of Thailand.svg COVIGEN [47]
Bionet Asia, Technovalia, University of Sydney
DNA Phase I (150) [48]
Double-blind, dose-ranging, randomised, placebo-controlled.
Feb 2021 Jun 2022, Australia, Thailand

Notes

    Related Research Articles

    Yong Poovorawan

    Yong Poovorawan is a professor of pediatrics at the Faculty of Medicine of Chulalongkorn University in Bangkok, Thailand. He is known for research in the fields of pediatric hepatology, viral hepatitis and virology, and avian influenza.

    Oxford–AstraZeneca COVID-19 vaccine Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

    The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant, and 61% against the Delta variant.

    CoronaVac Vaccine against COVID-19

    CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.

    The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

    COVID-19 vaccination in Australia Ongoing COVID-19 vaccine program in Australia

    The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, and will continue with the goal of vaccinating all willing Australians before 2022. Front-line workers and aged care staff and residents will be the first Australians to be inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine is not included in the Australian vaccination program.

    COVID-19 vaccination in Albania

    The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.

    COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

    The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The COVID-19 virus was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.

    COVID-19 vaccination in Africa Immunisation programme against COVID-19 in Africa

    COVID-19 vaccination programs have begun in many countries and territories in Africa. In June 2021, the World Health Organization predicted that 47 of Africa's 54 nations would fall short of the aim of vaccinating 10% of their people by September 2021. In June, Africa accounted for fewer than 1% of worldwide vaccine doses delivered.

    The National Advisory Committee on Immunization is an advisory body that provides the Government of Canada with medical and scientific advice relating to human immunization.

    COVID-19 vaccination in Vietnam Plan to immunize against COVID-19 in Vietnam

    The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.

    COVID-19 vaccination in South Korea Plan to immunize against COVID-19

    COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

    COVID-19 vaccination in Indonesia

    The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.

    COVID-19 vaccination in Bangladesh Immunisation programme against COVID-19 in Bangladesh

    Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

    Sputnik Light Vaccine against COVID-19

    Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. It will also be used as a third (booster) dose for those who received Sputnik V at least 6 months earlier.

    COVID-19 vaccination in Japan

    COVID-19 vaccination in Japan started later than in most other major economies. The country has frequently been regarded as "slow" in its vaccination efforts.

    COVID-19 vaccination in Brazil

    The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started on January 17, 2021, when the country had 210 thousand deaths.

    COVID-19 vaccine clinical research

    COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. Thirty vaccines are authorized for use by national governments, including eight approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.

    References

    1. 1 2 3 "Covid-19 Vaccination Dashboard" (in Thai). MOPH. 24 Dec 2021. Retrieved 24 Dec 2021.
    2. "UCINFO" (in Thai). NHSO. 27 Aug 2021. Retrieved 27 Aug 2021.
    3. "เรื่องน่ารู้ของวัคซีนโควิด-19 ที่ไทยสั่งซื้อ". BBC ไทย (in Thai). Retrieved 5 January 2021.
    4. "ทำความรู้จัก ออกซ์ฟอร์ด-แอสทราเซเนกา วัคซีนที่ไทยเลือก". มติชนออนไลน์ (in Thai). 2 January 2021. Retrieved 5 January 2021.
    5. "ครม.ไฟเขียวงบซื้อวัคซีนโควิดเพิ่ม35ล้านโดส ฉีดให้คนไทย66ล้าน". โพสต์ทูเดย์ (in Thai). Retrieved 5 January 2021.
    6. "นายกฯ สำนึกในพระมหากรุณาธิคุณ ร.10 ทรงให้ "สยามไบโอไซเอนซ์" รองรับวัคซีนโควิด-19". BBC ไทย (in Thai). 27 November 2020. Retrieved 5 January 2021.
    7. "'ซีพี' ทุ่ม 1.5 หมื่นล้านบาท ลงทุน บ.ผลิตวัคซีน 'ซิโนแวค'". กรุงเทพธุรกิจ (in Thai). Retrieved 5 January 2021.
    8. "ข่าวดี ไทยเริ่มผลิตวัคซีน "โควิด-19" ในประเทศ รอบที่ 2 แล้ว". ไทยรัฐ (in Thai). 3 January 2021. Retrieved 5 January 2021.
    9. "Thailand gov't negotiating to buy Pfizer coronavirus vaccine". AP. 20 April 2021.
    10. "Thai-developed COVID vaccine to proceed to human trials". Al Jazeera. 18 February 2021.
    11. Limited, Bangkok Post Public Company. "Thai-made vaccine ready 'by next year'". Bangkok Post. Retrieved 2021-04-09.
    12. Zimmer, Carl (2021-04-05). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times. ISSN   0362-4331 . Retrieved 2021-04-09.
    13. "'Sorry' for slow vaccine supply". Bangkok Post. Retrieved 29 July 2021.
    14. "Fate of 100m-dose vaccination hangs in the air". Bangkok Post. Retrieved 29 July 2021.
    15. "Thailand plans to mix Sinovac and AstraZeneca vaccines. Critics say that's risky". CNN. Retrieved 29 July 2021.
    16. "Brain swelling killed mixed-vaccine recipient". Bangkok Post. Retrieved 29 July 2021.
    17. "วัคซีนโควิด19 แอสตราเซเนกา ล็อตแรกถึงประเทศไทย". Hfocus (in Thai). 2021-02-24. Retrieved 2021-07-18.
    18. 1 2 3 4 isranews (2021-08-18). "เจาะห้องประชุม ศบค.อัพเดตสถานะ 7 วัคซีนในไทย ก่อนเคาะซื้อ'ซิโนแวค'เพิ่ม 12 ล้านโดส". สำนักข่าวอิศรา (in Thai). Retrieved 2021-08-18.
    19. 1 2 "Infographic/Quote". mhesi.
    20. 1 2 3 isranews (2021-09-27). "เช็คมาตรการคุมโควิด คลายล็อก 9 กิจกรรม รวม 'โรงหนัง-ฟิตเนส' ลดเคอร์ฟิว 22.00-04.00 น." สำนักข่าวอิศรา (in Thai). Retrieved 2021-09-27.
    21. 1 2 3 4 5 "เปิด 5 วัคซีนป้องกัน COVID ที่ขึ้นทะเบียนในไทยแล้ว". Thai PBS (in Thai). Retrieved 24 June 2021.
    22. "อนุทิน เร่งกระจายแอสตร้าเซนเนก้า 1 ล้านโดส พร้อมซื้อวัคซีนเพิ่มครบ 150 ล้านโดส". Prachachat (in Thai). Retrieved 24 June 2021.
    23. "ทูตฝรั่งเศสขอนำเข้าวัคซีน "จอห์นสันฯ" ฉีดประชากรตนเองในไทย". Hfocus (in Thai). 2021-02-24. Retrieved 2021-07-28.
    24. "COVID-19 Vaccination Services For French Citizens At Bangkok Hospital Headquarters". Bangkok Hospital Group. 2021-02-24. Retrieved 2021-07-28.
    25. "ด่วน อย. อนุมัติขึ้นทะเบียนวัคซีน "ไฟเซอร์" แล้ว". Prachachat (in Thai). Retrieved 24 June 2021.
    26. 39 (2021-07-20). "1.5 Million Pfizer Vaccine Doses, Donated by the United States, Arrive in Thailand". US Embassy Thailand. Retrieved 30 July 2021.CS1 maint: numeric names: authors list (link)
    27. pum (2021-08-05). "สธ. เผยเริ่มฉีดไฟเซอร์แล้ววันนี้ หลังส่งวัคซีนให้ครบ 10 จังหวัด". ประชาชาติธุรกิจ (in Thai). Retrieved 2021-08-05.
    28. matichon (2021-08-17). "ครม. จัดซื้อวัคซีนไฟเซอร์เพิ่มเติม 10 ล้านโดส รวมเป็น 30 ล้านโดส เริ่มทยอยส่งมอบได้ไตรมาส 4". มติชนออนไลน์ (in Thai). Retrieved 2021-08-17.
    29. isranews (2021-09-29). "'ไฟเซอร์' ล็อตจัดซื้อถึงไทยแล้ว 2 ล้านโดส ส่งตรวจคุณภาพ ก่อนกระจายให้กับพื้นที่". สำนักข่าวอิศรา (in Thai). Retrieved 2021-09-29.
    30. ""องค์การเภสัชกรรม" ชี้แจง การจัดหาวัคซีนทางเลือก "โมเดอร์นา" 5 ล้านโดส คาด มีการสั่งซื้อต้นเดือน ส.ค. 64". Manager Online (in Thai). Retrieved 24 June 2021.
    31. "เริ่มแล้ว 'เมดพาร์ค' ประเดิมฉีด 'โมเดอร์นา' นำร่องฉีดวัคซีน mRNA".
    32. "'โมเดอร์นา' ถึงไทยแล้ว ใกล้ได้ปักเข็ม ส่ง รพ.เอกชน 10% ทุกแห่งทั่วประเทศ ปชช.ตรวจสอบ-โอนสิทธิได้". November 2021.
    33. ""รจภ. นำเข้า "โมเดอร์นา" วัคซีนตัวเลือกชนิดที่ ๒ กระตุ้นภูมิคุ้มกัน ในปี ๒๕๖๕". Chulabhorn Royal Academy (in Thai). Retrieved 18 Oct 2021.
    34. "วัคซีนซิโนฟาร์มล็อตแรกถึงไทย 1 ล้านโดส". BBC Thai (in Thai). Retrieved 24 June 2021.
    35. "ราชวิทยาลัยจุฬาภรณ์ เริ่มฉีดวัคซีน "ซิโนฟาร์ม" ให้ผู้ด้อยโอกาส-ผู้สูงอายุ". Thairath (in Thai). Retrieved 25 June 2021.
    36. "'ซิโนฟาร์ม' ล็อต 7 จำนวน 2 ล้านโดส ถึงไทยแล้ว". www.bangkokbiznews.com/ (in Thai). 29 August 2021. Retrieved 2021-08-30.
    37. "ราชวิทยาลัยจุฬาภรณ์ แจ้ง วัคซีนซิโนฟาร์ม ล็อต 9 จำนวน 4 ล้านโดส ถึงไทยแล้ว". bangkokbiznews (in Thai). 2021-09-12. Retrieved 2021-09-12.
    38. "คำแนะนำการฉีดวัคซีนโควิด 19". Department of Disease Control, Ministry of Public Health (Thailand) via Facebook (in Thai). Retrieved 13 Jan 2022.
    39. https://ddc.moph.go.th/vaccine-covid19/getFiles/11/1628849610213.pdf
    40. "มีผลทันที ยกเลิกซิโนแวค 2 เข็ม ปรับสูตรฉีดแอสตร้าฯ บูสเตอร์เข็ม 3". Prachachat (in Thai). Retrieved 22 Sep 2021.
    41. "สธ.ยันไทยยกเลิกใช้สูตรแอสตร้าฯ 2 เข็มแล้ว เหตุไม่ทันต่อเดลต้า ปรับใช้สูตรไขว้ทั่วประเทศ". Matichon (in Thai). Retrieved 22 Sep 2021.
    42. "Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand". ClinicalTrials.gov . 21 February 2021. NCT04764422. Retrieved 7 April 2021.
    43. Zimmer C (April 5, 2021). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times . Retrieved 7 April 2021.
    44. "ChulaCov19 mRNA Vaccine in Healthy Adults". ClinicalTrials.gov . 28 September 2020. NCT04566276. Retrieved 21 March 2021.
    45. Rujivanarom, Pratch (6 June 2021). "Local jabs yet to join Covid fight". Bangkok Post. Retrieved 8 July 2021.
    46. "A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19". ClinicalTrials.gov . 7 July 2021. NCT04953078. Retrieved 7 July 2021.
    47. "COVALIA study update: first healthy volunteers dosed in needle-free SARS-CoV2 DNA vaccine phase 1 trial". Bionet Asia. 30 June 2021. Retrieved 19 July 2021.
    48. "The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (COVALIA)". ClinicalTrials.gov . 8 February 2021. NCT04742842.